Table 5.
The Situation of 13 Patients with Advanced Cancer Who Had Hepatitis B Reactivation After Using ICIs
| Patients Characteristics | Baseline | At reactivation | Antiviral Treatment | Time for Achieving HBV-DNA Undetectable (Weeks) | Time for ALT Recovery (Weeks) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reference | Patient | Age | Gender | Country | Cancer Type | ICIs | Combined Treatment | HBV-DNA | Antiviral Prophylaxis | Weeks From Start of ICI | HBV-DNA(copies/ml) | Peak AST/ALT(U/L) | Anti-PD-1/PD-L1 Therapy Disruption | |||
| Zhang X 2019(a) | 1 | 48 | M | China | NPC | Camrelizumab | No | Undetectable | No | 3 | 7.81×103 | ALT=191.4 | Delayed | Entecavir | 1 | 2 |
| 2 | 47 | M | China | NPC | Camrelizumab | No | Undetectable | No | 16 | 6.98 × 104 | ALT=203 | Delayed | Entecavir | 4 | 4 | |
| 3 | 39 | M | China | Melanoma | Pembrolizumab | No | Undetectable | No | 28 | 2.10 × 103 | ALT=27.6 | No | Not use | 5 | Not reported | |
| 4 | 36 | M | China | HCC | Nivolumab | No | Undetectable | Entecavir | 12 | 1.80 × 103 | ALT=298 | Discontinued | Entecavir+tenofovir | 1 | 3 | |
| 5 | 45 | M | China | H&NSCC | Toripalimab | No | Undetectable | No | 35 | 4.04 × 106 | ALT=281.2 | Delayed | Entecavir | 3 | 6 | |
| 6 | 41 | F | China | Sarcoma | Nivolumab | No | Undetectable | No | 20 | 6.00 × 107 | ALT=465.1 | Not reported | Entecavir | 8 | 4 | |
| Byeon S 2020 | 7 | 59 | M | Korea | NSCLC | Nivolumab | No | 70 IU/ml | Tenofovi | 3 | 2.81× 103 | AST G1 | Delayed | Tenofovi | 4 weeks PD die | Not reported |
| 8 | 60 | M | Korea | NSCLC(adenocarcinoma) | Pembrolizumab | No | Undetectable | Entecavir | 4 | 1.48 × 103 | Normal | Delayed | Entecavir | 4 | Not reported | |
| 9 | 45 | M | Korea | NSCLC(adenocarcinoma) | Pembrolizumab | No | 1553 IU/ml | Entecavir | 4 | 1.13 × 104 | Normal | No | Entecavir | 599 IU/ml | Not reported | |
| Koksal AS 2017 | 10 | 56 | M | Turkey | Melanoma | Ipilimumab*4 cycle,Nivolumab | No | Unknown | No | 14 | 2.45 × 105 | 845/888 | No | Tenofovir | 11week(183IU/ml) | 11 |
| Pandey A 2018 | 11 | 51 | M | USA | NSCLC(adenocarcinoma) | Pembrolizumab | Whole Brain radiation | Unknown | No | 4 | >1.70× 108 | 670/994 | No | Tenofovir | 10 | 10 |
| Ragunathan K 2017 | 12 | 51 | M | USA | metastatic adenocarcinoma of the lung | Pembrolizumab | No | Unknown | No | 2 | >170.0 IU/ml | 217/615 | Not reported | Not reported | Not reported | Not reported |
| Lake AC 2017 | 13 | 72 | M | USA | NSCLC(adenocarcinoma) | Nivolumab | No | Undetectable | Dolutegravir/Abacavir | 13 | >1.7 × 105 | 520/474 | Delayed | Dolutegravir /Tenofovir | 14 | 9 |
| He MK 2021 | 14 | Not reported | M | China | HCC | Pembrolizumab | No | 1.65e2 IU/mL | Tenofovir | 6 | 2.85×104 | ALT=198.2 | Discontinued | Entecavir | 7 | 5 |
| 15 | Not reported | M | China | HCC | Pembrolizumab | HAIC | 3.83e6 IU/ml | Tenofovir | 14 | 4.86×103 | ALT=271.6 | Delayed | Tenofovir | 9 | 6 | |
| 16 | Not reported | M | China | HCC | Toripalimab | HAIC | Undetectable | Entecavir | 6 | 1.31×103 | ALT=39.6 | No | Entecavir | 1 | Not reported | |
| 17 | Not reported | M | China | HCC | Nivolumab | HAIC | 5.86e3IU/ml | Entecavir | 12 | 1.58×103 | ALT=208.5 | Delayed | Entecavir | 3 | 3 | |
| 18 | Not reported | M | China | HCC | Sintilimab | HAIC | Undetectable | Entecavir | 4 | 2.98×103 | ALT=151 | Delayed | Entecavir | 4 | 3 | |
| 19 | Not reported | M | China | HCC | Toripalimab | HAIC | Undetectable | Entecavir | 16 | 1.21×103 | ALT=174.8 | Delayed | Tenofovir | 2 | 3 | |
| 20 | Not reported | M | China | HCC | Toripalimab | HAIC | Undetectable | Entecavir | 4 | 1.21×103 | ALT=378.8 | Delayed | Entecavir | 7 | 6 | |